118 related articles for article (PubMed ID: 37972835)
1. Dual targeting of DR5 and VEGFR2 molecular pathways by multivalent fusion protein significantly suppresses tumor growth and angiogenesis.
Isakova AA; Artykov AA; Plotnikova EA; Trunova GV; Khokhlova VА; Pankratov AA; Shuvalova ML; Mazur DV; Antipova NV; Shakhparonov MI; Dolgikh DA; Kirpichnikov MP; Gasparian ME; Yagolovich AV
Int J Biol Macromol; 2024 Jan; 255():128096. PubMed ID: 37972835
[TBL] [Abstract][Full Text] [Related]
2. DR5-Selective TRAIL Variant DR5-B Functionalized with Tumor-Penetrating iRGD Peptide for Enhanced Antitumor Activity against Glioblastoma.
Yagolovich AV; Isakova AA; Artykov AA; Vorontsova YV; Mazur DV; Antipova NV; Pavlyukov MS; Shakhparonov MI; Gileva AM; Markvicheva EA; Plotnikova EA; Pankratov AA; Kirpichnikov MP; Gasparian ME; Dolgikh DA
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293545
[TBL] [Abstract][Full Text] [Related]
3. Optimized Heterologous Expression and Efficient Purification of a New TRAIL-Based Antitumor Fusion Protein SRH-DR5-B with Dual VEGFR2 and DR5 Receptor Specificity.
Yagolovich AV; Artykov AA; Isakova AA; Vorontsova YV; Dolgikh DA; Kirpichnikov MP; Gasparian ME
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682540
[TBL] [Abstract][Full Text] [Related]
4. Application of an Autoinduction Strategy to Optimize the Heterologous Production of an Antitumor Bispecific Fusion Protein Based on the TRAIL Receptor-Selective Mutant Variant in Escherichia coli.
Isakova A; Artykov A; Vorontsova Y; Dolgikh D; Kirpichnikov M; Gasparian M; Yagolovich A
Mol Biotechnol; 2023 Apr; 65(4):581-589. PubMed ID: 36094644
[TBL] [Abstract][Full Text] [Related]
5. Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.
Huet HA; Growney JD; Johnson JA; Li J; Bilic S; Ostrom L; Zafari M; Kowal C; Yang G; Royo A; Jensen M; Dombrecht B; Meerschaert KR; Kolkman JA; Cromie KD; Mosher R; Gao H; Schuller A; Isaacs R; Sellers WR; Ettenberg SA
MAbs; 2014; 6(6):1560-70. PubMed ID: 25484045
[TBL] [Abstract][Full Text] [Related]
6. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting.
Lingasamy P; Laarmann AH; Teesalu T
Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014
[TBL] [Abstract][Full Text] [Related]
7. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity.
Pavet V; Beyrath J; Pardin C; Morizot A; Lechner MC; Briand JP; Wendland M; Maison W; Fournel S; Micheau O; Guichard G; Gronemeyer H
Cancer Res; 2010 Feb; 70(3):1101-10. PubMed ID: 20103630
[TBL] [Abstract][Full Text] [Related]
8. Antihepatoma peptide, scolopentide, derived from the centipede scolopendra subspinipes mutilans.
Hu YX; Liu Z; Zhang Z; Deng Z; Huang Z; Feng T; Zhou QH; Mei S; Yi C; Zhou Q; Zeng PH; Pei G; Tian S; Tian XF
World J Gastroenterol; 2023 Mar; 29(12):1875-1898. PubMed ID: 37032730
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation).
Zhou X; Lv L; Tan Y; Zhang Z; Wei S; Xiao S
Brain Res; 2021 Sep; 1766():147515. PubMed ID: 33984327
[TBL] [Abstract][Full Text] [Related]
10. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H
Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953
[TBL] [Abstract][Full Text] [Related]
11. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
12. Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo.
Szabo E; Schneider H; Seystahl K; Rushing EJ; Herting F; Weidner KM; Weller M
Neuro Oncol; 2016 Sep; 18(9):1242-52. PubMed ID: 27009237
[TBL] [Abstract][Full Text] [Related]
13. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
14. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
15. VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.
Michaelsen SR; Staberg M; Pedersen H; Jensen KE; Majewski W; Broholm H; Nedergaard MK; Meulengracht C; Urup T; Villingshøj M; Lukacova S; Skjøth-Rasmussen J; Brennum J; Kjær A; Lassen U; Stockhausen MT; Poulsen HS; Hamerlik P
Neuro Oncol; 2018 Oct; 20(11):1462-1474. PubMed ID: 29939339
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
17. A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.
Toriyama S; Horinaka M; Yasuda S; Taniguchi T; Aono Y; Takamura T; Morioka Y; Miki T; Ukimura O; Sakai T
Mol Cancer Ther; 2016 Sep; 15(9):2066-75. PubMed ID: 27406983
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells.
Ivanov VN; Zhou H; Partridge MA; Hei TK
Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
